BULLETIN BOARD Latest data on adalimumab therapy for ankylosing spondylitis, rheumatoid arthritis and psoriatic arthritis
نویسنده
چکیده
Results recently presented at the Annual refractory to them over time. Adalimumab Of those who had experienced no response European Congress of Rheumatology in Paris, France, suggests that adalimumab is safe and effective in patients with ankylosing spondylitis, rheumatoid arthritis and psoriatic arthritis who are not responding to anti-TNF therapy. In a recent series of studies, adalimumab was found to be well tolerated and effective in patients with a number of arthritic conditions who had failed standard therapy, providing a potential second-line treatment option in these patients.
منابع مشابه
Comparing Biologic Cost Per Treated Patient Across Indications Among Adult US Managed Care Patients: A Retrospective Cohort Study
BACKGROUND The relative cost of biologics in the treatment of autoimmune disorders, including rheumatoid arthritis, psoriatic arthritis, psoriasis, and ankylosing spondylitis, is a key consideration for managed care payers. OBJECTIVES Our objective was to estimate biologic costs and treatment patterns in US managed care patients with rheumatoid arthritis, psoriatic arthritis, psoriasis, and/o...
متن کاملAdalimumab in the treatment of rheumatoid arthritis.
Adalimumab (ADA), a fully human monoclonal antibody against TNF-α is indicated for the treatment of rheumatoid arthritis (RA), psoriatic arthritis, ankylosing spondylitis, juvenile idiopathic arthritis, Crohn's disease, ulcerative colitis and psoriasis. In RA, it may be prescribed in combination with methotrexate or other disease-modifying antirheumatic drugs or as monotherapy. Studies comparin...
متن کاملAdalimumab: a new alternative biologic agent for chronic plaque psoriasis.
The results of a phase III European multicentre trial comparing adalimumab, placebo and methotrexate are published in this issue. An accompanying article examines the quality of life impacts derived from the same study. Adalimumab has been licensed for use in severe rheumatoid arthritis in combination with methotrexate and in psoriatic arthritis, ankylosing spondylitis and Crohn's disease. A li...
متن کاملAdalimumab in the treatment of arthritis
Tumor necrosis factor (TNF) has been implicated in a number of arthritic disease states, including rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. Adalimumab is the first fully human, high-affinity, recombinant immunoglobulin G(1) (IgG(1)) anti-TNF monoclonal antibody. Adalimumab in combination with methotrexate or standard antirheumatic therapies, or as monotherapy, is e...
متن کاملReview of Biosimilars of Adalimumab.
A first fully humanized monoclonal antibody approved by US Food and Drug Administration (FDA) in 2002 was Adalimumab. Clinical efficacy and safety of adalimumab has been assessed in various trials in rheumatoid arthritis, ankylosing spondylitis, psoriasis, psoriatic arthritis, Crohn's Disease, and ulcerative colitis. It is one of the major sales success among biological and still one of the gre...
متن کامل